A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

PHASE3CompletedINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

March 4, 2011

Primary Completion Date

November 4, 2014

Study Completion Date

November 4, 2014

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Fluticasone Furoate/Vilanterol

Inhaled corticosteroid/long acting beta-agonist

DRUG

Vilanterol

Inhaled long acting beta-agonist

DRUG

Placebo

Placebo

Trial Locations (72)

1000

GSK Investigational Site, Manila

1100

GSK Investigational Site, Quezon City

1501

GSK Investigational Site, Moss

1600

GSK Investigational Site, Pasig

2040

GSK Investigational Site, Kløfta

2400

GSK Investigational Site, Dagupan

2408

GSK Investigational Site, Elverum

3019

GSK Investigational Site, Marilao, Bulacan

4005

GSK Investigational Site, Stavanger

5000

GSK Investigational Site, Jaro, Iloilo City

10400

GSK Investigational Site, Bangkok

10700

GSK Investigational Site, Bangkok

10717

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

10789

GSK Investigational Site, Berlin

11000

GSK Investigational Site, Muang

15213

GSK Investigational Site, Pittsburgh

20253

GSK Investigational Site, Hamburg

21502

GSK Investigational Site, Geesthacht

23552

GSK Investigational Site, Lübeck

24210

GSK Investigational Site, Abingdon

27103

GSK Investigational Site, Winston-Salem

28152

GSK Investigational Site, Shelby

28207

GSK Investigational Site, Charlotte

29303

GSK Investigational Site, Spartanburg

29340

GSK Investigational Site, Gaffney

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

29640

GSK Investigational Site, Easley

29678

GSK Investigational Site, Seneca

29707

GSK Investigational Site, Fort Mill

29732

GSK Investigational Site, Rock Hill

30096

GSK Investigational Site, Duluth

32174

GSK Investigational Site, Ormond Beach

32608

GSK Investigational Site, Gainesville

32720

GSK Investigational Site, DeLand

32789

GSK Investigational Site, Winter Park

32825

GSK Investigational Site, Orlando

35294

GSK Investigational Site, Birmingham

37601

GSK Investigational Site, Johnson City

39112

GSK Investigational Site, Magdeburg

40002

GSK Investigational Site, Khon Kaen

43215

GSK Investigational Site, Columbus

46123

GSK Investigational Site, Avon

47904

GSK Investigational Site, Lafayette

49684

GSK Investigational Site, Traverse City

50200

GSK Investigational Site, Chiang Mai

55000

GSK Investigational Site, Nan

60596

GSK Investigational Site, Frankfurt am Main

63141

GSK Investigational Site, St Louis

63301

GSK Investigational Site, Saint Charles

65000

GSK Investigational Site, Muang

66606

GSK Investigational Site, Topeka

73103

GSK Investigational Site, Oklahoma City

78539

GSK Investigational Site, Edinburg

83814

GSK Investigational Site, Coeur d'Alene

85006

GSK Investigational Site, Phoenix

90505

GSK Investigational Site, Torrance

92663

GSK Investigational Site, Newport Beach

97504

GSK Investigational Site, Medford

134060

GSK Investigational Site, Seoul

411706

GSK Investigational Site, Ilsanseo-gu, Goyang-si, Gyeonggi-do

47304-5547

GSK Investigational Site, Muncie

04910

GSK Investigational Site, Elsterwerda

01069

GSK Investigational Site, Dresden

04109

GSK Investigational Site, Leipzg

425-707

GSK Investigational Site, Ansan

501-757

GSK Investigational Site, Gwangju

614-735

GSK Investigational Site, Pusan

134-090

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

152-703

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01336608 - A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD | Biotech Hunter | Biotech Hunter